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Abstract The chemokine CXCL12 (stromal cell-derived
factor-1, SDF-1) and its receptor CXCR4 play a major role in
tumor initiation, promotion, progression and metastasis, espe-
cially for breast cancer cells. Recently, CXCR7 has been iden-
tified as a second receptor for CXCL12; nevertheless, it also
binds CXCL11 (interferon-inducible T cell α chemoattractant,
I-TAC). However, little is known about the co-expression of
the two receptors and their interactions. Quantitative reverse
transcription plus the polymerase chain reaction has demon-
strated that both receptors are frequently co-expressed in breast
cancer cell lines, whereas other tumor cell lines often express
only one of them. For interaction studies, we chose MCF-7
breast cancer cells, since they highly express CXCR4 and
CXCR7 at the protein level but not CXCR3 (another target
for CXCL11). Immunofluorescence and gold–labeling by light
and electronmicroscopy, respectively, revealed that both recep-
tors were localized at the cell surface in non-stimulated cells.
After exposure to CXCL12 or CXCL11, the receptors were
rapidly internalized alone or in close proximity. Stimulation
with the CXCR4- or CXCR7-selective non-peptide antagonists
AMD3100 and CCX733 resulted not only in single internali-
zation but partly also in co-internalization of the two receptors.
Furthermore, both chemokine ligands reduced staurosporine-
induced apoptosis and caspase-3/7 activation; however, the
selective inhibitors merely had partial inhibitory effects on
these biological responses. Our findings suggest that CXCR4
and CXCR7 closely interact in breast cancer cells. Both are
co-internalized, transduce signals and induce further biolog-
ical effects partly independently of a selective stimulus or
antagonist.
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Introduction
Chemokines were initially discovered as small, 8- to 10-kDa
chemotactic cytokines in the immune system; they attract
leukocytes by interacting with their G-protein-coupled
seven-transmembrane domain receptors. Later, chemokines
and their receptors were shown to exhibit a much broader
function in tissue development and homeostasis and in many
pathological conditions (for a review, see Mentlein et al.
2013). In particular, they play decisive roles in tumor initia-
tion, promotion, progression and metastasis (for a review, see
Zlotnik et al. 2011). With respect to the last-mentioned, the
chemokine CXCL12/SDF-1 (stromal cell-derived factor-1)
and its receptor CXCR4 have attracted great interest as they
direct CXCR4-expressing breast cancer cells to peripheral
tissues such as lung, liver, lymph nodes and bone marrow
where the ligand CXCL12 is constitutively produced (Müller
et al. 2001). However, the interactions and regulations of
chemokines and their receptors are highly complex and also
in this case, the initially simple model has had to be modified
(for a review, see Hattermann and Mentlein 2013). Namely, a
second receptor for CXCL12 was recently de-orphanized and
named CXCR7/RDC1 (Balabanian et al. 2005; Burns et al.
2006). In addition to CXCL12, CXCR7 binds with ten-fold
lower affinity to CXCL11/I-TAC (interferon-inducible T cell
α chemoattractant), which is also a ligand for CXCR3 (which
is targeted also by CXCL9/Mig and CXCL10/IP-10).
At first, CXCR7 was thought to be merely a non-signaling
decoy or scavenger receptor, since because of alterations in a
conserved DRYLAIV-motif, it fails to couple to G-proteins
(Naumann et al. 2010; Thelen and Thelen 2008) and does not
cause Ca2+ mobilization upon activation, as is known for most
chemokine receptors (Burns et al. 2006). However, recent
reports show that CXCR7 signals alternatively through β-
arrestin (Rajagopal et al. 2010) and thus directly mediates
several cellular effects, in addition to its function in controlling
extracellular CXCL12 levels. In cells expressing solely
CXCR7, stimulation by CXCL12 or CXCL11 results in the
phosphorylation of the kinases Erk (extracellular-signal regu-
lated kinases (p42/p44)) and Akt, for example, in human
leukocytes, vascular smooth muscle, rat glial, or human glio-
blastoma cells (Balabanian et al. 2005; Rajagopal et al. 2010;
Hattermann et al. 2010; Ödemis et al. 2012). Regarding cel-
lular responses, CXCR7 stimulation enhances cell survival of
tumor cells, e.g., by reduction of temozolomide-induced apo-
ptosis in glioblastoma cells or of cell adhesion (Burns et al.
2006; Miao et al. 2007; Hattermann et al. 2010, 2012).
However, some cell types, especially endothelial and
distinct tumor cells, express the two CXCL12-receptors,
CXCR4 and CXCR7, in combination (Miao et al. 2007;
Heinrich et al. 2012) and they may regulate one another’s
function. This can be studied by use of selective antagonists,
by application of CXCL11 (if CXCR3 is absent), or by
silencing/overexpression. Here, partially divergent reports ex-
ist. For example, CXCR7-activation can block CXCR4-
driven transendothelial migration of lymphoma cells (Zabel
et al. 2009), can impair CXCL12-induced tube formation of
endothelial progenitor cells (Yan et al. 2012), facilitate
CXCR4-mediated neuronal migration (Sanchez-Alcaniz
et al. 2011) and enhance CXCR4-promoted chemotaxis
in vitro but decreases matrix degradation and invasion
in vivo in CXCR4-overexpressing MTLn3 breast cancer
cells (Herandez et al. 2011). Indeed, CXCR4-CXCR7
heterodimerization has been recently observed by biochemical
methods in transfected HEK cells (Levoye et al. 2009;
Décaillot et al. 2011) and the ligand CXCL12 might also
homodimerize even at low concentrations (Ray et al. 2012a).
Thus, cellular responses to CXCL12 (and CXCL11) might
depend on the relative expression of the two receptors or on
the cell type. Therefore, more clarification of their interactions
is urgently required. Since breast cancer cells are an important
target, we examined the expression of CXCR4 and CXCR7
in various cell lines and selected MCF-7 cancer cells as a
representative that expresses both receptors at comparable
levels but not CXCR3. We investigated the localization of
CXCR4 and CXCR7, before and after chemokine-stimulation
of these cells, by fluorescence and electron microscopy and
evaluated the influence of receptor-selective antagonists on




Recombinant human chemokines and growth factors were
from Pepro Tech (Rocky Hill, N.J., USA; CXCL11) or
Immunotools (Friesoythe, Germany; CXCL12, epidermal
growth factor). Staurosporine was purchased from
Calbiochem (Merck-Calbiochem, Darmstadt, Germany). The
non-peptide antagonist AMD3100 (= plerixafor, Mozobil,
selective for CXCR4) was obtained from Sigma-Aldrich
(St. Louis, Mo., USA) and CCX733 (selective for CXCR7)
was a generous gift from Mark E.T. Penfold from
ChemoCentryx (Mountain View, Calif., USA). Staurosporine
and antagonists were dissolved in dimethylsulfoxide and dilut-
ed from these stock solutions.
Cell cultures and stimulations
MCF-7 mamma carcinoma cells were obtained from the
American Type Culture Collection (ATTC) via Cell Line
Service, Eppelheim, Germany and cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10 % fetal calf serum (FCS) and 1 % penicillin/streptomycin
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(P/S; all from PAN Biotech, Aidenbach, Germany); other
mamma carcinoma cell lines (T47D, BT549, MDA-MB231)
were obtained and kept as described elsewhere (Stark et al.
2007). The glioma cell line U343 was obtained from the
Deutsches Krebsforschungszentrum (Heidelberg, Germany;
cf. Mentlein and Held-Feindt 2002), cultivated in 10 %
DMEM+10 % FCS+1 % P/S; melanoma cells (LOX, Mel6,
Mel Juso), small cell lung cancer cells (OH1, OH2 and SW2)
and the neuroblastoma cell line SH-SY5Y were generously
supplied by Prof. Dr. Udo Schumacher (Department of
Anatomy, University of Hamburg, Germany) and character-
ized and cultivated as described (Thies et al. 2007; Lange et al.
2011). All cells were routinely checked for Mycoplasma con-
tamination by 4′,6-diamidino-2-phenylindole (DAPI) staining
and Mycoplasma-specific polymerase chain reaction (PCR;
Minerva Biolabs, Berlin, Germany).
Quantitative reverse transcription plus PCR
RNA was isolated with the Qiazol Lysis reagent (Qiagen,
Hilden, Germany) and digested by DNase. cDNA was
synthesized and real-time reverse transcription plus PCR
(RT-PCR) was performed (Ludwig et al. 2005) by using the
following TaqMan primer probes (Applied Biosystems, Foster
City, Calif., USA): human glyceraldehyde 3-phosphate dehy-
drogenase (hGAPDH; Hs99999905_m1), hCXCL11
(Hs00171138_m1), hCXCL12 (Hs00171022_m1), hCXCR3
(Hs00171041_m1), hCXCR4 (Hs00607978_s1) and
hCXCR7 (Hs00664172_s1). Cycles of thresholds (CT) were
determined with an ABI PRISM 7000 sequence detection
system and ΔCT values=CTGene of interest - CTGAPDH were
calculated. A ΔCT value of 3.33 corresponds to one magnitude
lower gene expression compared with GAPDH. For each gene,
logarithmic linear dependence of CT-values from the numbers
of copies was verified by using various amounts of cDNA.
Western blotting and enzyme-linked immunoassay
Western blot experiments were performed as previously de-
scribed (Hattermann et al. 2008). CXCR7 was detected with
anti-CXCR7 (ab 38089, rabbit, 1:500; Abcam, Cambridge,
Mass., USA); re-blotting was performed with anti-caveolin-1
(N-20, rabbit, 1:200; Santa Cruz Biotechnology, Santa Cruz,
Calif., USA). For analysis of kinase phosphorylation, blots
were incubated with anti-phosphorylated Erk (pErk1/2;
Thr202/Tyr204; 1:500; Cell Signaling Technology, Danvers,
Mass., USA) and re-probed after stripping with methanol and
0.1 mol/l glycine/HCl buffer, pH 2.5, with anti-Erk2 (1:500;
Santa Cruz).
Enzyme-linked immunoassay (ELISA) for CXCL12 was
performed with culture supernatants and standards, with
recombinant protein being applied to Nunc Maxisorb
48-well plates (Nunc, Roskilde, Denmark) for 2 h at room
temperature. After removal of samples, wells were blocked
with 1 % bovine serum albumin (BSA) and 0.02 % Tween in
phosphate-buffered saline (PBS) for 1 h, washed three times
with PBS at pH 7.4, incubated with anti-CXCL12 (1:500;
anti-SDFα, rabbit polyclonal, ab9797, Abcam), washed with
PBS (3×), incubated with horseradish-peroxidase-labeled
anti-rabbit IgG (1:1000, raised in goats, sc2030, Santa Cruz
Biotechnology), washed (3×) and finally exposed to 100 μl
3,3′,5,5′-tetramethylbenzidine substrate (Thermo Scientific
Pierce, Waltham, Mass., USA), the reaction being stopped
with 50 μl 0.5 M H2SO4. Extinction at 450 nm was measured
against a reference wavelength (620 nm).
Internalization experiments and fluorescence light
and electron microscopy
Subconfluent cells were grown on poly-D-lysine-coated cov-
erslips in DMEM plus 10 % FCS for 1 day, washed with PBS
plus 0.5 % BSA and equilibrated twice (1 h each) with
DMEM plus 0.5 % fatty-acid-free BSA (Sigma-Aldrich).
The cells were then gradually cooled to 4 °C and exposed
(at 4 °C) to primary antibodies (for fluorescence light micros-
copy: rabbit anti-CXCR4, 1:100, Imgenex IMG-125, San
Diego, Calif., USA; for electron microscopy: goat anti-
CXCR4, 1:100, Abcam ab1671; fluorescence light and elec-
tron microscopy: mouse anti-CXCR7, 1:100, Chemocentrxy
11G8) for 45 min at 4 °C. For secondary antibody controls,
primary antibodies were omitted. After being washed, cells
were then incubated in the same medium with secondary
antibodies for 45 min at 4 °C. For light microscopy, Alexa-
Fluor-labeled donkey anti-mouse IgG 488 and donkey anti-
rabbit IgG 555 (1:800 each; Invitrogen, Carlsbad, Calif.) were
applied as secondary antibodies. For electron microscopy,
colloidal-gold-labeled donkey anti-goat IgG with 15-nm gold
(Aurion, Wageningen, The Netherlands) and, after several
rinses, goat anti-mouse IgG (British BioCell, Cardiff, UK)
conjugated to 5-nm gold were used as secondary antibodies.
After two washes, medium was replaced with fresh medium
(4 °C) containing ligands or antagonists. Cells were then
warmed to 37 °C for various times (or left at 4 °C as controls)
and fixed with Zamboni’s fixative consisting of 4 % formal-
dehyde freshly prepared from paraformaldehyde with 17.5 %
saturated picrinic acid in phosphate buffer for fluorescence
microscopy or with 4 % formaldehyde freshly prepared from
paraformaldehyde and 0.5 % glutaraldehyde in PBS for elec-
tron microscopy. For fluorescence light microscopy, fixed
cells were washed with PBS, incubated with Alexa-Fluor-
647-labeled wheat germ agglutinin (WGA, 1:200, 10 min;
Invitrogen), counterstained with DAPI and inspected with a
Zeiss Axiovert 200 M microscope with ApoTome.
Measurements of cytosolic:surface ratio were performed as
described in Supplementary Fig. 1. For electron microscopy,
specimens were washed with PBS, exposed to 2 % osmium
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tetroxide for 30 min, dehydrated in series with increasing
ethanol concentrations and embedded in Araldite. Ultrathin
(60 nm) sections were cut, contrasted in saturated uranyl
acetate for 2 min and viewed under a Zeiss 902 electron
microscope at a primary magnification of ×50,000 (cf.
Krisch et al. 1998).
Apoptosis and caspase assays
Cell death assays were performed in DMEM plus 0.2 % FCS
for the indicated times. For detection of nuclei with signs of
apoptosis, namely nuclear fragmentation and/or chromatin
condensation, cells were seeded on poly-D-lysine-coated cov-
erslips, grown overnight and then treated with staurosporine,
chemokines and antagonists for 24 h. After being rinsed with
PBS, cells were fixed with ice-cold acetone/methanol (1:1;
10 min) and washed (3×) with PBS. Nuclei were stained with
DAPI for 30 min (modified after Nicoletti et al. 1991).
Damaged nuclei were evaluated and counted by a non-
biased person.
Caspase-3/7 activity was measured after an 8-h exposure to
toxic agents and chemokines by collecting adherent and non-
adherent cells by centrifugation for 5 min at 1000g, washes
with PBS and lysis in 100-200 μl 0.1 % Nonidet P40 (NP40),
10 mM dithiothreitol, 1 mM EDTA, 100 mMNaCl in 50 mM
HEPES buffer, pH 7.4. After a freeze-thaw cycle (30 min at -
70 °C) and protein determination of an aliquot by the Bradford
assay, samples were adjusted to equal protein concentrations
and volumes (50 μg protein/250 μl) and incubated with
250 μl 40 μM N-Ac-Asp-Glu-Val-Asp-AMC (Ac-DEVD-
AMC; Bachem, Torrance, Calif., USA; AMC, 7-amino-4-
methylcoumarine) in lysis buffer at 37 °C. Fluorescence
of liberated AMC was determined after various times
(λEx=360 nm; λEm=460 nm) and the maximum value was set
as 100 %. Controls were performed with identical incubations
in the presence of 0.6 nM N-Ac-Asp-Glu-Val-Asp-aldehyde
(Ac-DEVD-CHO), a potent and selective inhibitor of
caspases-3/7 and subtracted from the values.
Statistical analysis
Values are given as means±standard deviations (SD).
Statistical significance was analyzed by a paired two-tailed
Student’s t-test; *P<0.05, **P<0.01, ***P<0.001.
Results
CXCR4 and CXCR7 are both expressed and produced
by breast cancer cells
In an initial experiment, we investigated the expression
of the chemokine receptors CXCR7 and CXCR4 in various
breast cancer and other tumor cell lines by quantitative
RT-PCR and Western blots (Fig. 1). Whereas the inves-
tigated breast cancer cells mostly transcribed (at differ-
ent levels) both receptors, other tumor cell lines tested
displayed a more restricted or no detectable expression
(Fig. 1a). CXCR7 is prominent in human glioma cell
lines such as U343 or A772 cells, as previously report-
ed (Hattermann et al. 2010; with more examples). In
contrast, the small cell lung cancer cell lines OH1, OH2
and SW2 transcribed all CXCR4 but were CXCR7-
negative. Among melanoma cell lines, some were neg-
ative for both receptors; others showed expression of
the one or other receptor. The frequently used neuro-
blastoma cell line SH-SY5Y showed a relative high
CXCR4 mRNA level but was CXCR7-negative. Hence,
many but not all types of cancer cells express CXCR4 or
CXCR7 in various combinations.
Since MCF-7 cells are established mamma carcinoma cells
and transcribe both chemokine receptors at comparably high
levels, we selected this cell line in order to study their inter-
action in an exemplary cell line. Receptor production at the
protein level was verified by Western blot (Fig. 1c) and by
immunocytochemistry (Fig. 2). Quantitative RT-PCR
confirmed the absence of CXCR3, a competing receptor
for CXCL11 and demonstrated a moderate production
of the ligands CXCL11 and CXCL12 (Fig. 1b). To
evaluate self-stimulation effects, endogenously produced
CXCL12 was determined by ELISA of culture superna-
tants. After 24 h in culture, 500,000 MCF-7 cells pro-
duced 187±7 ng CXCL12 (in 1 ml medium, n=3±S.D.)
yielding a concentration of about 23±1 nM. However,
in most experiments, much lower cell numbers and incu-
bations times were employed ensuring a much lower concen-
tration during stimulations (less than 0.1 nM). Furthermore,
cells were carefully washed prior to experiments in order to
exclude self-stimulation and to ensure the recovery of
internalized receptors.
CXCR4 and CXCR7 are jointly internalized upon ligand
or antagonist stimulation
On living cells, receptors can be labeled at 4 °C by antibodies
directed against their extracellular domains and visualized
by use of differently fluorescent-labeled or gold-labeled
secondary antibodies by using fluorescence or electron
microscopy, respectively. On resting cells, both receptors
can be readily stained at the cell surface by fluorescence
(Figs. 2 and 3) and electron (Fig. 4) immunocytochem-
istry. As seen in the merged images of fluorescence by
light microscopy or directly with the gold particles by
electron microscopy, receptors are located separately and
in close association.
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Fig. 1 Expression of chemokine receptors in MCF-7 and other tumor
cells of various origin. a Transcription of chemokine receptors CXCR4
and CXCR7 in various types of tumor cells was determined by quantita-
tive reverse transcription plus the polymerase chain reaction (RT-PCR).
ΔCT values relatve to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) are given (n=3±S.D.); ΔCT=3.33 corresponds to one magni-
tude. Breast cancer cell lines show various levels of CXCR4 and CXCR7
transcription; mostly, both receptors are co-expressed. In contrast to
mamma carcinoma cells, glioma cells (U343) exhibit a preferential
CXCR7 expression (for more data, see Hattermann et al. 2010), whereas
small cell lung cancer cells (OH1,OH2, SW2) and the neuroblastoma cell
line (SH-SY5Y) transcribe only CXCR4. In melanoma cell lines, both
receptors are either not detectable (LOX) or singularly transcribed (inMel
Juso, only CXCR4; in Mel6, only CXCR7). b Transcription of chemo-
kine ligands and receptors in MCF-7 breast cancer cells as determined by
quantitative RT-PCR (qRT-PCR; see a). CXCR4 and CXCR7 are both
transcribed but not CXCR3 (but primers/probe yield a signal with T cells
as positive controls, not shown). Moreover, the CXCR4/7 ligand
CXCL12 is expressed at a low level, whereas the CXCR3/7 ligand
CXCL11 is just above the detection limit. c Western blots of chemokine
receptors CXCR4 and CXCR7 in membrane fractions of various types of
human tumor cells clearly reveal a dual production of CXCR4 and
CXCR7 in MCF-7 breast cancer cells, a single expression of CXCR7 in
U343 glioma cells and an absence of both receptors in LOX melanoma
cells, as also found by qRT-PCR (caveolin-1: loading control)
Cell Tissue Res (2014) 357:253–266 257
Fig. 2 Internalization of chemokine receptors CXCR4 and CXCR7 into
MCF-7 cells upon stimulation with various ligands, as visualized by
immuno-fluorescence light microscopy. a Chemokine receptors were
immuno-labeled at 4 °C with red (CXCR4) and green (CXCR7) fluores-
cent (secondary) antibodies in resting cells. Without stimulation, recep-
tors were scattered alone or lay in close proximity at the cell surface. b For
secondary antibody controls, primary antibodies were omitted. c-h Inter-
nalization was induced by stimulation with various ligands at various
times at 37 °C. After exposure to chemokines CXCL12 (10 nM; c, e) or
CXCL11 (10 nM; d, f) or to non-peptide receptor-selective antagonists
AMD3100 (1 μM; g) or CCX733 (0.1 μM; h) receptors were rapidly
internalized mostly or partly together (see also inserts)
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Fig. 3 Measurement of CXCR4 and CXCR7 localization. a-f Chemo-
kine receptors were immuno-stained and internalization was induced by
stimulation at 37 °C (cf. Fig. 2). Membranes were stained with Alexa-
Fluor-647-labeled wheat germ agglutinin (WGA, here displayed in cyan).
g Based on the membrane signal, the intensity of CXCR4 and CXCR7
signals was measured, yielding the cytosolic:surface ratio (means±SD).
Unstimulated cells yielded low ratios (most receptors were on the sur-
face), whereas both chemokines and synthetic antagonists yielded high
ratios (most receptors were found intracellularly). For each stimulus, at
least 10 cells were analyzed from two independent experiments (the
quantification method is depicted in Supplementary Fig. 1)
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After exposure to 37 °C, both receptors were rapidly inter-
nalized in the presence of ligands or antagonists and finally
found in intracellular vesicles (Figs. 2, 3, 4). As seen best in
immunofluorescence, CXCL12 stimulation initially resulted
in a mostly separate internalization of both receptors (5 min,
Fig. 2c, insert) as detected by separate red and green dots and a
lower frequency of yellow (merged fluorescence) dots.
However, after 10 min, nearly all dots were intracellularly
located (Fig. 2e). With CXCL11, which binds only to
CXCR7, similar internalization kinetics were observed but
co-internalization of the two receptors was somewhat delayed;
namely, after 5 min, red and green dots were located separate-
ly but at 10 min, the images were mostly similar to those of
CXCL12 (Fig. 2d, f).
Semi-quantification of receptor internalization was
achieved by labeling the glycocalyx of the cell surface
with WGA (a lectin that binds to sialic acid and N-
acetyl-D-glucosamine) and determining the ratio of sur-
face versus intracellular chemokine receptor fluorescence
(Fig. 3; see Supplementary Fig. 1 for method).
Exposure of the receptor-labeled cells to selective non-
peptide antagonists AMD3100 or CCX733 (see Discussion)
also yielded internalization of the receptors (Figs. 2g, h, 3e, f).
Again, apart from receptor-selective internalization, namely
CXCR4 by AMD3100 and CXCR7 by CCX733, co-
internalization of the two receptors by their respective selec-
tive antagonist also occurred.
These results show that, on resting cells, both receptors are
located at the cell surface alone or in close proximity. Upon
stimulation with CXCL12 or CXCL11, rapid internalization
of both chemokine receptors occurs. Furthermore, CXCR4
is also internalized by the CXCR7-ligand CXCL11 sug-
gesting an interaction of both receptors. Not only expo-
sure to ligands but also exposure to selective antagonists
results in rapid receptor internalization. In addition to morpho-
logical connections, we next wanted to determine whether
signal transductions and biological effects of both receptors
were interconnected.
Signal transduction is initiated through both receptors
by CXCL12 stimulation
When MCF-7 cells were stimulated with CXCL12, we
observed phosphorylation of the kinases Erk1/2 in Western
blots with a phosphorylation-specific antibody (Fig. 5).
Phosphorylation could be significantly diminished by the
receptor-selective non-peptide antagonists AMD3100 (for
CXCR4) and by CCX733 (for CXCR7); each inhibitor in-
duced no effects on its own (Fig. 5). These experiments
show that stimulation by CXCL12 induces, in MCF-7 cells, a
signal transduction that can be inhibited by receptor-selective
non-peptide antagonists.
CXCR4 and CXCR7 mediate apoptosis resistance
To evaluate whether selective pharmacological inhibition also
triggers combined biological effects, we measured anti-
Fig. 4 Internalization of chemokine receptors CXCR4 and CXCR7 in
MCF-7 cells upon stimulation with various ligands visualized by
immuno-gold electron microscopy. CXCR4 was immuno-labeled by
15-nm gold particles and CXCR7 by smaller 5-nm gold particles at
4 °C. Internalization was followed under stimulation with various
ligands at various times at 37 °C, as correspondingly described in
Fig. 2 (arrowheads gold particles). a–d On resting cells, both labels were
found on the cell surface mostly alone as single dots but also sometimes
in close proximity as clusters of small and large dots. e–l Upon ligand-
induced stimulation, receptors were internalized and found in intracellular
vesicles. Here, they frequently accumulated in groups of dots of one
or mixed sizes. This co-internalization was observed either with
CXCL11 as the CXCR7-selective ligand (e-h) or with CXCL12 as
the ligand for both receptors (i-l). To improve the visualization of
the gold particles, sections were only weakly exposed to osmium
tetroxide and lead citrate
Fig. 5 Phosphorylation of the extracellular-signal-regulated kinases
Erk1/2 (p42/p44) in MCF-7 cells upon stimulation with CXCL12 in the
absence and presence of CXCR4- and CXCR7-specific antagonists (pErk
phosphorylated Erk, Ctrl control with antagonists alone). a, b Cells were
stimulated for 15 min at 37 °C with ligand (1 or 10 nM), antagonists
(AMD3100, 10 μM; CCX733, 0.1 μM), combinations, or a positive
control (10 ng/ml epidermal growth factor, EGF), lysed and analyzed
by Western blots probed with antibodies for the phosphorylated kinases
and GAPDH (or re-probed for Erk2, not shown) to ensure equal loading.
Example of several independent stimulations (top) and means±SD of
densitometry of n=5 experiments (bottom). Stimulations were
performed in serum-free media plus 0.1 % bovine serum albumin
on washed and 1-h-pre-equilibrated cells. The inhibitors were
added from stock solutions in dimethylsulfoxide (DMSO, 0.1 %
final concentrations) at 1 h prior to the experiment; a correspond-
ing amount of DMSO was added to all other cultures
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apoptotic effects previously preferentially attributed to
CXCR7 (Hattermann et al. 2010). Apoptosis could be induced
in MCF-7 cells by treatment with staurosporine. After 24 h,
about 40 % of the cells showed apoptotic nuclei at a concen-
tration of 100 nM staurosporine (Fig. 6b, Supplementary
Fig. 2). Co-incubation with both chemokines, CXCL11 or
CXCL12, reduced apoptotic nuclei about 25 % (Fig. 6c).
The CXCL12-induced reduction of apoptosis could be
inhibited by the CXCR7-selective antagonist CCX733 but
not by the CXCR4-selective antagonist AM3100 (Fig. 6d). To
corroborate these morphological findings by biochemical
measurements, the activity of the effector caspases-3/7 was
determined. After an 8-h exposure to 100 nM staurosporine,
caspase-3/7 activity was more than 10-fold higher than that of
controls (Fig. 6e). Again, CXCL11 or CXCL12 efficiently
reduced this increase by 40-50 %. Whereas the CXCR4-
antagonist AMD3100 did not influence CXCL12-induced
apoptosis induction, the CXCR7-antagonist reduced the che-
mokine effect.
These experiments show that CXCL11 and CXCL12
both reduce chemically induced apoptosis. However,
this anti-apoptotic effect is better inhibited by the CXCR7
antagonist.
Discussion
Among chemokine receptors, CXCR4 has been found to be
most widely expressed in many types of tumors and has been
shown to be involved in tumor cell invasion, metastasis,
survival and proliferation (Müller et al. 2001; for a review,
see Zlotnik et al. 2011). Reports on the occurrence and bio-
logical role of the newly discovered second receptor for the
CXCR4-ligand CXCL12, namely CXCR7, in tumors are
emerging (Burns et al. 2006; Miao et al. 2007; Wang et al.
2008; Hattermann et al. 2010; for a review, see Hattermann
and Mentlein 2013). Few but often conflicting results have
been published on the interaction of CXCR4 and CXCR7.
Knowledge of the interactions between both CXCL12 recep-
tors is of particular importance in tumor biology, because they
are co-expressed on many tumor cells, including breast cancer
cells and on tumor endothelial cells and tumor-associated
macrophages (Miao et al. 2007; Hattermann et al. 2010;
Heinrich et al. 2012). Since MCF-7 cells express both recep-
tors at comparable levels, we used them as a model to inves-
tigate the internalization of CXCR4 and CXCR7 and to elu-
cidate the biological effects of the common ligand CXCL12 or
the specific CXCR7-ligand CXCL11 and during the applica-
tion of selective antagonists.
By immunolabeling of intact cells, we were able to
localize both receptors clearly at the cell surface by fluores-
cence and electron microscopy. This partly contrasts with a
few reports that are based on immunocytochemistry of fixed
cells and that claim a preferential intercellular localization of
CXCR7 (Luker et al. 2010; Ray et al. 2012b). However,
localization of CXCR7 has also been demonstrated at the cell
surface (Kumar et al. 2012; Hattermann et al. 2012). Pre-
labeling of resting cells (without internalization, at 4 °C) with
antibodies has now clearly established the cell surface local-
ization of both receptors. Culture conditions, e.g., serum con-
tent or pre-stimulation, might greatly influence localization at
the cell surface or intracellularly. By means of immuno-
fluorescence and electron-microscopy, we were also able to
show that, upon stimulation, both receptors are internalized
rapidly and in close contact. Our findings corroborate exper-
iments with transfected HEK-293 cells investigated by biolu-
minescence resonance energy transfer, which revealed the
heterodimerization of overexpressed CXCR4 and CXCR7
receptors (Levoye et al. 2009). Interestingly, stimulation
with receptor-specific agonists and even with non-peptide
antagonists results in pronounced co-internalization of the
receptors.
Chemokine receptors are composed of about 340-370 ami-
no acids with a short acidic N-terminal extracellular domain,
seven helical transmembrane domains plus three intracellular
and three extracellular hydrophilic loops and an intracellular
C-terminus containing serine and threonine residues that act as
phosphorylation sites during receptor regulation (Allen et al.
2007). Receptor desensitization and internalization is
achieved by agonist-dependent phosphorylation of the C-
terminal tail, thereby promoting the binding of β-arrestins
Fig. 6 Inhibition of staurosporine-induced apoptosis and caspase-3/7
activation by CXCL11 and CXCL12 in MCF-7 cells and influence of
selective CXCR4 and CXCR7 inhibitors. Apoptosis was induced by 100
nM staurosporine in DMEM+0.2 % FCS and analyzed by quantification
of apoptotic nuclei after 24 h or by measurement of caspase-3/7-activity
after 8 h. a, b Visualisation of normal nuclei (a) and nuclei with signs of
apoptosis (b, arrows nuclei damaged by fragmentation and/or chromatin
condensation). c Both chemokine ligands, namely 5 nM CXCL11 and 1
nM CXCL12, significantly reduced staurosporine-induced apoptosis. d
This anti-apoptotic effect could be reversed by co-incubation with the
CXCR7-selective antagonist CCX733 (0.1 μM) but not significantly by
CXCR4-selective antagonist AMD3100 (5 μM). Both antagonists had no
inhibitory effects on their own (not shown). Means of triplicate counting
of several inspection areas from n=4±SD individual stimulations by an
unbiased person. e Corroborating the morphological results, both
chemokine ligands, namely 5 nM CXCL11 and 1 nM CXCL12,
significantly reduced staurosporine-induced caspase-3/7 activation.
Again, the antagonist CCX733 (0.1 μM) but not AMD3100 (5 μM),
reduced this anti-apoptotic effect. Means of duplicate measurements from
n=3±SD individual stimulations (*P<0.05, **P<0.01, ***P<0.001).
Antagonists showed neither effect on basal or staurosporine-induced
capsase activities. Staurosporine and antagonists were added from
stock solutions in DMSO yielding a final concentration of 0.5 %;
therefore, corresponding amounts of DMSO were added to all other
incubations
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and internalization through clathrin-coated pits or lipid rafts/
caveolae (Canals et al. 2012). Stimulation of CXCR4 by
CXCL12 is known to activate heterotrimeric G-proteins
resulting in the dissociation of the Gα and Gβγ subunits,
which then activate downstream effectors (Busilo and
Benovic 2007). A DRY-motif (DRYLAIV) in the second
intracellular loop is thought to be essential for this G-
protein-mediated signaling. In contrast to CXCR4, CXCR7
lacks this domain and was initially regarded as a decoy recep-
tor that regulates CXCL12 levels (Naumann et al. 2010).
Nevertheless, recent studies have shown that CXCR7 can
signal via an alternative pathway, namely via β-arrestins that
are also involved in the internalization of G-protein-coupled
receptors (Rajagopal et al. 2010; Ödemis et al. 2012; Luttrell
et al. 2010). However, the issue of CXCR7 signaling is still
controversial.
Based on our observations and previously reported coupled
effects (Levoye et al. 2009; Ödemis et al. 2012), CXCR4-
CXCR7 heterodimers appear to be more distinct functional
units than the receptors alone (Fig. 7). Dual activating effects
on proliferation have been recently described in CXCR4-
CXCR7-coexpressing pancreatic cancer (Heinrich et al.
2012) or in Jurkat (Kumar et al. 2012) cells. As shown here,
CXCL12-induced kinase phosphorylation in MCF-7 cells can
be inhibited by selective agonists of one or the other receptor.
In contrast, anti-apoptotic effects that are mediated by
CXCL12 and CXCL11 alone are mainly antagonized by
CCX733, the selective CXCR7 antagonist and not by
AMD3100 antagonizing CXCR4. However, AMD3100 has
been reported to act not solely as a simple CXCR4 antagonist
(Kalatskaya et al. 2009). As measured by bioluminescence
resonance energy transfer, AMD3100 also increases CXCL12
binding to CXCR7 and CXCL12-induced conformational
rearrangements in the receptor dimer. Moreover, small
increases in the potency of CXCL12-induced arrestin
recruitment to CXCR7 by AMD3100 have been observed
(Kalatskaya et al. 2009).
Thus, heterodimerization influences not only receptor in-
ternalization but also signal transduction and biological ef-
fects. Moreover, the pharmacological profiles of specific in-
hibitors are changed, as shown in our study.
Overall, the CXCL12-CXCR4-CXCR7-axis is highly
complex. The bioavailability of CXCL12 (and CXCL11)
is controlled by ligand dimerization (Ray et al. 2012a),
by binding to heparan sulfate glycosaminoglycans on
the cell surface (Allen et al. 2007), by proteolytic deg-
radation (Ludwig et al. 2002; Mentlein 2004) and by
receptor-mediated internalization (as shown here).
Biological effects depend on the receptor subtype
expressed by the particular cell type and on receptor
interactions, if both subtypes are expressed.
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